Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688987 | 1.00 | AKR1B1 (0.44) | AKR1B1AKR1A1ADAM17FPR2MMP8 | |
| SCHEMBL20135218 | 0.80 | LMNA (0.39) | AKR1B1ADAM17MMP8MMP14 | |
| SCHEMBL20134768 | 0.80 | ADAM17 (0.38) | ADAM17MMP8MMP14 | |
| SCHEMBL3412312 | 0.75 | ADAM17 (0.44) | ADAM17FPR2 | |
| SCHEMBL29688542 | 0.73 | ADAM17 (0.41) | AKR1B1ADAM17MMP8MMP14 | |
| SCHEMBL20134985 | 0.73 | ADAM17 (0.41) | AKR1B1ADAM17MMP8MMP14 | |
| SCHEMBL20134812 | 0.70 | MMP14 (0.54) | ADAM17MMP8MMP14 | |
| SCHEMBL29688652 | 0.70 | MMP14 (0.54) | ADAM17MMP8MMP14 | |
| SCHEMBL20135455 | 0.69 | LMNA (0.38) | ADAM17MMP8MMP14 | |
| SCHEMBL1173343 | 0.69 | AKR1B1 (0.50) | AKR1B1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | AKR1B1 2158/4885AKR1A1 2387/4885ADAM17 36/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | AKR1B1 2142/4885AKR1A1 2394/4885ADAM17 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.